MarginsXMarginsX
Home › Markets › BTAIQ

BioXcel Therapeutics, Inc. (BTAIQ)

BTAIQ is quoted over the counter, not listed on an exchange. BioXcel Therapeutics, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close · November 16, 2026
$0.0110
-8.3% on the day
1-year return
-99.3%
Market cap
$344K
Nano cap. From the Nov 16, 2026 close × 31.3M shares (10-Q cover page, Aug 11, 2026)
P/E and P/S
Net loss over the period · 0.5×
On trailing twelve months to June 30, 2026 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-16.

Profile

FieldValue
TickerBTAIQ, quoted over the counter
SEC CIK0001720893
OTC Markets tierPink (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressNew Haven, CT
Incorporated inDE

Warning signs

Cash runway
3.0 months
$12.8M cash at June 30, 2026
Share count, 1 year
+115.1%
2025-08-11 to 2026-08-11 · +1611.4% over 3 years
Going-concern doubt
Yes
10-Q filed August 13, 2026
Insider net buying, 12 months
-$36K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern."
10-Q 2026-08-13
Cash and burn$12.8M cash; operating cash flow -$12.7M a quarter.Report 2026-06-30
Shares outstanding31,305,499 (2026-08-11); 14,556,743 a year earlier; 29,267,197 three years earlier. 3y figure adjusted for split (1-for-16 overall).Cover page 2026-08-11
Reverse splits, 3 years1; latest 1-for-16 on 2025-02-10Source 2025-02-10
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-03-11
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-09-01
AuditorErnst & Young LLP, Stamford, Connecticut, United StatesPCAOB Form AP 2026-04-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $36K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$182K-$14.7M-$6.1M$12.8M$104.5M$742K10-Q 2026-08-13
Q1 2026
2026-03-31
$206K-$12.7M-$11.8M$17.2M$100.3M$680K10-Q 2026-05-15
Q4 2025
2025-12-31
$256K-$12.5M-$14.2M$28.4M$109.6M$642K10-K 2026-03-27
Q3 2025
2025-09-30
$98K-$30.9M-$18.8M$36.2M$109.1M$752K10-Q 2025-11-12
Q2 2025
2025-06-30
$120K-$19.2M-$12.6M$17.4M$108.7M$868K10-Q 2026-08-13
Q1 2025
2025-03-31
$168K-$7.3M-$12.0M$31.0M$105.5M$1.9M10-Q 2026-05-15
Q4 2024
2024-12-31
$366K-$10.9M-$14.8M$29.9M$102.5M$2.3M10-K 2026-03-27
Q3 2024
2024-09-30
$214K-$13.7M-$16.3M$40.4M$104.4M$2.3M10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-11
Latest annual report10-K2026-03-27
Latest quarterly / interim10-Q2026-08-13
Latest current report8-K2026-10-30
Latest proxyDEF 14A2025-11-12

Source: SEC EDGAR submissions feed, 672 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier